Greenbrook Tms Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Greenbrook Tms Inc (GBNH) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Greenbrook Tms Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 116M vs 2,789M combined for tracked competitors (4.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-31.4% annualized vs trailing 12 months), vs accelerating (+2.4%) for its tracked peer group.
- Growth: Greenbrook Tms Inc generated 12.9% revenue growth year over year in Q2 2024, vs -1.7% for its tracked competitors combined.
- Profitability: Its -62.3% net margin compares with -127.2% for the peer group.
- Peer revenue share: Greenbrook Tms Inc accounted for 2.7% of combined revenue among its tracked peer group, up from 2.4% a year earlier.
- Peer differentiation: Revenue per employee of $0.43M compares with $0.55M for the peer group (0.8x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
GBNH Sales vs. its Competitors, Q2 2024
Greenbrook Tms Inc reported revenue growth of 12.85 % year on year in Q2 2024, above its competitors' combined revenue change of -1.68 %.
With a net margin of -62.29 %, Greenbrook Tms Inc achieved higher profitability than its competitors (-127.19 %).
Greenbrook Tms Inc generated 2.72 % of the combined sales of its peer group, up from 2.38 % a year earlier.
Greenbrook Tms Inc vs. its Competitors, Q2 2024
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Greenbrook Tms Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Greenbrook Tms Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Greenbrook Tms Inc's competitor groups requires a Commercial License.
For context: the Healthcare Facilities industry grew revenue 14.7% year over year, combined, vs 12.9% for Greenbrook Tms Inc. Greenbrook Tms Inc's share of combined industry revenue moved from 0.02% to 0.02%, a gain of 0.00 percentage points.
Greenbrook Tms Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Greenbrook Tms Inc | No | - | - | Yes |
| Competitors combined (7) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
GBNH Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Definium Therapeutics Inc | 282.9% | Outperformed |
| 2 | Marpai Inc | 282.9% | Outperformed |
| 3 | American Well Corporation | 282.9% | Outperformed |
| 4 | Teladoc Health Inc | 282.9% | Outperformed |
| 5 | Shl Telemedicine Ltd | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Greenbrook Tms Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Greenbrook Tms Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Greenbrook Tms Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Greenbrook Tms Inc | 5.52 | 116.49 |
| Definium Therapeutics Inc | 4,229.26 | - |
| Agiliti Inc De | 1,363.43 | 1,177.45 |
| Teladoc Health Inc | 1,040.90 | 2,489.48 |
| American Well Corporation | 220.24 | 218.53 |
| Marpai Inc | 87.93 | 16.63 |
| SUBTOTAL | 6,999.56 | 4,082.58 |
Sign in to see all competitors of Greenbrook Tms Inc .
Sources: Greenbrook Tms Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Greenbrook Tms Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Greenbrook Tms Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Teladoc Health Inc | Teladoc Health Integrated Care 64.42 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Greenbrook Tms Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Greenbrook Tms Inc | 6 | 428,254 | -327,529 |
| Definium Therapeutics Inc | 4,229 | - | - |
| Agiliti Inc De | 1,363 | 1,471,814 | -35,856 |
| Teladoc Health Inc | 1,041 | 444,550 | -31,678 |
| American Well Corporation | 220 | 388,835 | -137,021 |
| Marpai Inc | 88 | 155,467 | -157,813 |
| PEERS TOTAL | 6,994 | 546,822 | -94,261 |
Sign in to see all peers for Greenbrook Tms Inc .
Greenbrook Tms Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Teladoc Health Inc | United States 80.07 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Greenbrook Tms Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Healthcare Facilities industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (77 companies). See the full Healthcare Facilities industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | -5.54 % | 52.28 % (avg) | -57.8 pp |
| Operating Margin | -70.27 % | industry median | -74.6 pp |
| EBITDA Margin | -64.51 % | 3.22 % (avg) | -67.7 pp |
| Capital Intensity (Capex / Revenue) | - | 4.01 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Greenbrook Tms Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenue Growth | - | 32.39 % | - |
| Operating Margin | -55.71 % | -44.43 % | - |
| Return on Invested Capital | -41.13 % | -99.90 % | - |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Greenbrook Tms Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Greenbrook Tms Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Greenbrook Tms Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 60.0 points above the industry aggregate.
Weaknesses
- Operating margin 74.6 points below the industry median.
- Latest-quarter revenue run-rate is decelerating (-31.4% annualized vs trailing 12 months).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (33.30 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Greenbrook Tms Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Greenbrook Tms Inc | 0.11 | 0.48 | - |
| Definium Therapeutics Inc | 3.23 | 5.69 | 0.10 |
| Agiliti Inc De | 0.08 | 1.71 | 1.15 |
| Teladoc Health Inc | 1.17 | 1.73 | 0.73 |
| American Well Corporation | 2.27 | 3.11 | - |
| Marpai Inc | 0.01 | 0.42 | - |
Sign in to see all peers for Greenbrook Tms Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Greenbrook Tms Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Greenbrook Tms Inc | Q2 2024 | +211.3 % | - |
| Definium Therapeutics Inc | Q2 2026 | - | - |
| Agiliti Inc De | Q1 2024 | +0.9 % | - |
| Teladoc Health Inc | Q2 2026 | -4.0 % | - |
| American Well Corporation | Q2 2026 | -26.6 % | - |
| Marpai Inc | Q2 2026 | -10.5 % | - |
| PEERS TOTAL | -2.6 % | - |
Sign in to see all peers for Greenbrook Tms Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Greenbrook Tms Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Greenbrook Tms Inc | Q2 2024 | -0.1 % | - |
| Definium Therapeutics Inc | Q2 2026 | - | - |
| Agiliti Inc De | Q1 2024 | +6.8 % | -0.5 % |
| Teladoc Health Inc | Q2 2026 | +0.2 % | -30.4 % |
| American Well Corporation | Q2 2026 | -21.4 % | - |
| Marpai Inc | Q2 2026 | -19.0 % | - |
Sign in to see all peers for Greenbrook Tms Inc .
Greenbrook Tms Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Greenbrook Tms Inc | - | - | - |
| Definium Therapeutics Inc | - | - | - |
| Agiliti Inc De | - | - | - |
| Teladoc Health Inc | - | - | - |
| American Well Corporation | - | - | - |
| Marpai Inc | - | - | - |
Sign in to see all peers for Greenbrook Tms Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Greenbrook Tms Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Greenbrook Tms Inc | - | 0.05 |
| Definium Therapeutics Inc | - | - |
| Agiliti Inc De | - | 1.16 |
| Teladoc Health Inc | - | 0.42 |
| American Well Corporation | - | 1.01 |
| Marpai Inc | - | 5.29 |
| PEERS AVERAGE | - | 1.71 |
Sign in to see all peers for Greenbrook Tms Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.